Swiss - Delayed Quote CHF

Santhera Pharmaceuticals Holding AG (SANN.SW)

14.92 +0.26 (+1.77%)

At close: November 6 at 5:30:15 PM GMT+1

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Santhera Pharmaceuticals CFO on AGAMREE growth in 2026 - One2One Investor Forum

Proactive 4d ago

SANN.SW
+1.77%
Santhera reports 101% revenue growth as AGAMREE expands across global markets

Proactive 1mo ago

SANN.SW
+1.77%
4565.T
Santhera nears cash break-even as AGAMREE gains traction, Edison says

Proactive 2mo ago

SANN.SW
+1.77%
S3F0.F

SANN
Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus

GlobeNewswire 3mo ago

SANN.SW
+1.77%
Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea

GlobeNewswire 5mo ago

SANN.SW
+1.77%
4565.T
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting

GlobeNewswire 5mo ago

SANN.SW
+1.77%
Santhera Publishes Agenda for its Annual General Meeting

GlobeNewswire 6mo ago

SANN.SW
+1.77%
Santhera Pharmaceuticals, AOTI, Poolbeg Pharma, Solvonis Therapeutics, IBT

Proactive 6mo ago

SANN.SW
+1.77%
AOTI.L

POLB.L
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors

GlobeNewswire 6mo ago

SANN.SW
+1.77%
Santhera Pharmaceuticals Holding AG (SPHDF) Full Year 2025 Earnings Call Highlights: Revenue ...

GuruFocus.com 6mo ago

SANN.SW
+1.77%
Santhera Pharmaceuticals CFO on strong FY25 performance & AGAMREE expansion

Proactive 6mo ago

SANN.SW
+1.77%
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU

GlobeNewswire 6mo ago

SANN.SW
+1.77%

Performance Overview

Return	SANN.SW	MSCI WORLD (^990100-USD-STRD)
YTD	+18.41%	+6.32%
1-Year	+42.10%	+8.80%
3-Year	+36.13%	--

U.S. markets closed

Santhera Pharmaceuticals Holding AG (SANN.SW)

Santhera Pharmaceuticals CFO on AGAMREE growth in 2026 - One2One Investor Forum

Santhera reports 101% revenue growth as AGAMREE expands across global markets

Santhera nears cash break-even as AGAMREE gains traction, Edison says

Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus

Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea

Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting

Santhera Publishes Agenda for its Annual General Meeting

Santhera Pharmaceuticals, AOTI, Poolbeg Pharma, Solvonis Therapeutics, IBT

Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors

Santhera Pharmaceuticals Holding AG (SPHDF) Full Year 2025 Earnings Call Highlights: Revenue ...

Santhera Pharmaceuticals CFO on strong FY25 performance & AGAMREE expansion

Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU